Comparison of Cognitive Rehabilitation versus Donepezil Therapy on Memory Performance, Attention, Quality of Life, and Depression among Multiple Sclerosis Patients
Table 2
Results from multivariate analyses of covariance (MANCOVA) comparing scores of posttests between groups.
CR estimate (CI 95%)
Control estimate (CI 95%)
Donepezil estimate (CI 95%)
Placebo estimate (CI 95%)
value
Everyday memory
83.89a (66.9, 100.7)
112.84 (92.6, 133.0)
93.78 (74.1, 113.4)
156.84 (135.5, 178.1)
F (3, 70) = 9.93 d = .336,
Prospective and retrospective memory
35.41 (31.9, 38.8)
48.76 (44.6, 52.8)
38.22 (34.2, 42.2)
51.79 (47.4, 56.1)
F (3, 70) = 16.08 d = 0.45,
Digit span memory
13.43 (12.6, 14.2)
10.77 (9.8, 11.7)
11.18 (10.2, 12.1)
10.35 (9.3, 11.3)
F (3, 70) = 10.41 d = 0.34,
Physical health
65.24 (60.4, 70.0)
49.99 (44.2, 55.7)
60.32 (54.7, 65.8)
49.56 (43.5, 55.5)
F (3, 70) = 8.44 d = 0.30,
Mental health
68.26 (62.1, 74.4)
45.43 (38.0, 52.8)
56.04 (48.8, 63.2)
36.78 (29.0, 44.5)
F (3, 70) = 15.58 d = 0.44,
Depression
11.74 (8.7, 14.6)
24.27 (20.7, 27.8)
18.46 (15.0, 21.9)
29.86 (26.1, 33.5)
F (3, 70) = 21.82 d = 0.52,
a Prediction adjusted with baseline covariate model MANCOVA; CR: cognitive rehabilitation; CI 95%: confidence interval 95%; d: hesitantly defined effect sizes as “small, d = 0 .2,” “medium, d = 0 .5,” and “large, d = 0.8,”
